Second Half Financial Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$572K Hold
2,273
0.23% 56
2026
Q1
$494K Sell
2,273
-110
-5% -$24.4K 0.22% 54
2025
Q4
$544K Hold
2,383
0.24% 43
2025
Q3
$552K Sell
2,383
-10
-0.4% -$2.04K 0.24% 44
2025
Q2
$444K Buy
2,393
+10
+0.4% +$1.86K 0.21% 49
2025
Q1
$499K Sell
2,383
-89
-4% -$17.3K 0.25% 47
2024
Q4
$439K Buy
2,472
+70
+3% +$12.9K 0.21% 59
2024
Q3
$474K Sell
2,402
-12
-0.5% -$2.24K 0.25% 59
2024
Q2
$414K Buy
2,414
+32
+1% +$5.3K 0.33% 27
2024
Q1
$434K Buy
2,382
+102
+4% +$17.6K 0.19% 46
2023
Q4
$353K Buy
2,280
+18
+0.8% +$2.62K 0.17% 37
2023
Q3
$337K Sell
2,262
-19,061
-89% -$2.8M 0.17% 30
2023
Q2
$2.87M Sell
21,323
-2,830
-12% -$415K 0.66% 48
2023
Q1
$3.85M Sell
24,153
-158
-0.6% -$24.2K 2.28% 12
2022
Q4
$3.59M Sell
24,311
-43
-0.2% -$6.59K 2.34% 13
2022
Q3
$3.27M Sell
24,354
-14,965
-38% -$2.15M 4.07% 9
2022
Q2
$4.25M Hold
39,319
3.27% 5
2022
Q1
$4.25M Buy
+39,319
New +$5.71M 3.27% 5

Other funds holding ABBV

Second Half Financial Partners's ABBV Position: Q2 2026 in Review

Second Half Financial Partners held its AbbVie (ABBV) position steady in Q2 2026 at 2,273 shares worth $572K. The position accounts for 0.23% of the portfolio, ranked #56.

Second Half Financial Partners first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. The position peaked at $4.25M in Q2 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Second Half Financial Partners held 2,273 shares of AbbVie worth $572K as of Q2 2026.
  • Second Half Financial Partners left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.23% of Second Half Financial Partners's portfolio in Q2 2026, its #56 holding.
  • Second Half Financial Partners first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
  • Second Half Financial Partners's AbbVie position peaked at $4.25M in Q2 2022.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Second Half Financial Partners's 13F filing for Q2 2026, filed 17 Jul 2026.